Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: T-DXd
Sponsor: Beijing 302 Hospital